SARS-CoV-2 suppression with novel combinatorial AAV-RNAi vectors News | BioQuant | May 04th, 2022 Grimm Lab and collaborators at CIID present new recombinant AAV vectors, which inhibit coronavirus infection ex vivo and in vivo. Mol. Ther. 30(5):P2005-2023 (2022) Read the original publication in Molecular Therapy. For more information, follow Grimm Lab's Twitter thread.